Document:

EX-10.5

 Exhibit 10.5 
  

 
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

This Amended and Restated Employment Agreement (the “Agreement”) is entered into by and between Achillion Pharmaceuticals, Inc., a
Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Martha Manning (the “Executive”). The Agreement shall take effect as of the later of the dates set
forth in the signature page below (the “Effective Date”). Until the Effective Date, the Executive’s February 1, 2016 Employment Agreement with the Company (the “Initial Agreement”) will remain in force and effect and
continue to govern the Executive’s employment with the Company. 
 WHEREAS, the Company and the Executive desire to amend and restate
the Initial Agreement by entering into this Agreement; and 
 WHEREAS, the Company desires to continue to employ the Executive and the
Executive desires to continue to be employed by the Company pursuant to the terms and conditions set forth in this Agreement. 
 NOW,
THEREFORE, in consideration of the mutual covenants hereinafter set forth, the parties hereto agree to be bound, as of the Effective Date, as follows: 

1. Term of Employment. Subject to the terms and conditions of this Agreement, and provided that the Executive remains employed by the
Company as of the Effective Date, the Company agrees to continue to employ the Executive, and the Executive hereby accepts continued employment with the Company, for the period commencing on the Effective Date and ending on December 31, 2017,
unless earlier terminated pursuant to the provisions of Section 5 or extended pursuant to the provisions herein (such period, the “Employment Period”). On January 1, 2018, and on each yearly anniversary of such date thereafter,
this Agreement shall automatically renew for successive one-year periods unless, at least six (6) months prior to the applicable expiration date, either party has notified the other party that the
Agreement shall not so renew. 
 2. Title; Capacity. During the Employment Period, the Executive shall continue to serve as Executive
Vice President and General Counsel. The Executive shall be based at the Company’s headquarters in New Haven, Connecticut, or such place or places in the continental United States as the Board of Directors of the Company (the “Board”)
shall determine. The Executive shall be subject to the supervision of, and shall have such authority as is delegated to the Executive by, the Company’s Chief Executive Officer (“CEO”) and the Board. 

The Executive hereby accepts such continued employment and agrees to undertake the duties and responsibilities inherent in such position and
such other duties and responsibilities as the CEO or the Board shall from time to time reasonably assign to the Executive. The Executive agrees to devote her entire business time, attention and energies to the business and interests of the Company
during the Employment Period. The Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein which may be adopted from time to time by the Company. The Executive will be
eligible to participate in the Company’s performance review process. 

 3. Compensation and Benefits. 

3.1 Salary. The Company shall continue to pay the Executive, in periodic installments in accordance with the Company’s customary
payroll practices, a base salary at the biweekly rate of $13,073.08 (which if annualized equals $339,900) (the “Base Salary”). Such Base Salary may be increased in the sole discretion of the Board. 

3.2 Performance Bonus. Following the end of each fiscal year and subject to the approval of the Board, the Executive shall be eligible
to receive a discretionary retention and performance bonus (the “Performance Bonus”). The target amount of such Performance Bonus will be 35% of the Executive’s Base Salary for the applicable fiscal year (the “Target
Bonus”), based on the Company’s achievement of its performance goals for the applicable fiscal year and the Executive’s achievement of her performance goals for the applicable fiscal year, both as determined by the Board in its sole
discretion. The Executive’s individual performance goals for each fiscal year will be established by the CEO and the Board on an annual basis in consultation with the Executive. The Executive must be an active employee of the Company on the
date any Performance Bonus is distributed in order to be eligible for and to earn any bonus award, as it also serves as an incentive to remain employed by the Company. 

3.3 Fringe Benefits. The Executive shall continue to be entitled to participate in all benefit programs that the Company establishes and
makes available to its Executives, to the extent that the Executive is eligible under the plan documents governing those programs. Benefits are subject to change at any time in the Company’s sole discretion. The Executive shall be entitled to
20 days of paid time off (“PTO”) per calendar year, until and unless the Executive has been employed by the Company for at least five years, in which event the Executive shall be entitled to 25 days of PTO each calendar year. PTO shall be
subject to the accrual, use, and carryover provisions set forth in the Company’s vacation policy. 
 3.4 Reimbursement of
Expenses. The Company shall reimburse the Executive for all reasonable travel, entertainment and other expenses incurred or paid by the Executive in connection with, or related to, the performance of her duties and responsibilities under this
Agreement, in accordance with the policies and procedures, and subject to the limitations, adopted by the Company from time to time. 
 3.5
Commuting Assistance. The Company agrees to pay the Executive $20,000 each year in which she commutes between Pennsylvania and Connecticut (the “Commuting Compensation”). The Commuting Compensation shall be paid in two equal
installments (one in January and one in July) (each, a “Commuting Compensation Installment”), for the purpose of covering expenses incurred by the Executive in commuting between Pennsylvania and Connecticut, including travel expenses,
temporary housing expenses near the Company’s Connecticut office, and meal expenses. At the time each Commuting Compensation Installment is paid to the Executive, the Company shall also pay to the Executive an amount such that the after-tax amount actually received by the Executive is equal to the gross amount of the Commuting Compensation Installment paid on such date. 

 3.6 Withholding. All compensation payable to the Executive shall be subject to applicable
taxes and withholding. 
 4. Equity Acceleration in Connection with Change in Control. If a Change in Control Date occurs during the
Employment Period, then, effective upon the Change in Control Date, (a) the vesting schedule of each outstanding option to purchase shares of Common Stock of the Company held by the Executive shall be accelerated in part so that the option
shall become exercisable, as of immediately prior to the Change in Control, for an additional number of shares equal to 50% of the original number of shares of Common Stock subject to the option with the remaining unvested shares subject to such
option continuing to vest, subject to satisfaction of the vesting conditions, with respect to the same number of shares as would have become vested on each vesting date under the original remaining vesting schedule set forth in the applicable option
agreement, but with the remaining length of the vesting schedule shortened accordingly; and (b) unvested shares or units, if any, with respect to each outstanding restricted stock or stock unit award held by the Executive shall become
accelerated in part so that the number of unvested shares or units shall, as of immediately prior to the Change in Control, be reduced by the number of shares or units equal to 50% of the original number of shares or units subject to such restricted
stock or stock unit award with the remaining unvested shares or units continuing to vest, subject to satisfaction of the vesting conditions, with respect to the same number of shares or units as would have become vested on each vesting date under
the original remaining schedule set forth in the applicable restricted stock or stock unit award agreement, but with the remaining length of the vesting schedule shortened accordingly; provided that the vesting will not accelerate the distribution
of shares underlying equity awards if such acceleration of distribution would trigger taxation under Section 409A(a)(l)(B) of the Internal Revenue Code of 1986 and the guidance issued thereunder (“Section 409A” of the
“Code”). For the avoidance of doubt, the equity acceleration upon a Change in Control provided for in this Section 4 shall be in lieu of, and not in addition to, any equity acceleration provided for in any applicable equity award
agreement in connection with a Change in Control (a “CIC Duplicative Provision”). The Executive agrees that any CIC Duplicative Provision is hereby deleted and of no further force or effect. 

5. Termination of Employment Period. This Agreement and the employment of the Executive shall terminate upon the occurrence of any of
the following: 
 5.1 Expiration of the Employment Period by notice of non-renewal in accordance with
Section 1; 
 5.2 At the election of the Company for Cause, immediately upon written notice by the Company to the Executive, which
notice shall identify the Cause upon which the termination is based; 
 5.3 At the election of the Executive for Good Reason (as defined
below), pursuant to the provisions set forth below; 
 5.4 Upon the death or Disability (as defined below) of the Executive; 

 5.5 At the election of the Company without Cause, upon not less than fifteen (15) days’
prior written notice of termination; or 
 5.6 At the election of the Executive without Good Reason, upon not less than fifteen
(15) days’ prior written notice of termination. 
 6. Effect of Termination. 

6.1 Termination by the Company Without Cause or by the Executive for Good Reason Within 12 Months Following a Change in Control. If,
within 12 months following a Change in Control Date, either the Executive’s employment is terminated by the Company without Cause (other than due to her Disability or death) or the Executive resigns for Good Reason (a “Change in Control
Termination”), then, following the Executive’s date of termination (the “Date of Termination”) and subject to the conditions of Section 7 and in accordance with the timing and payment terms set forth in Section 7: 

(a) the Company shall, for a period of 12 months beginning on the Payment Commencement Date, continue to pay to the Executive, in accordance
with the Company’s customary payroll practices, her then current Base Salary as severance; 
 (b) if the Executive is eligible for and
timely elects to continue receiving group medical and/or dental insurance under the continuation coverage rules known as COBRA, the Company will continue to pay the share of the premium for such coverage that it pays for active and
similarly-situated employees who receive the same type of coverage (single, family, or other) until the earlier of (x) the end of the 12th month after the Date of Termination, and
(y) the date the covered individual’s COBRA continuation coverage expires, unless, as a result of a change in legal requirements, the Company’s provision of payments for COBRA will violate the nondiscrimination requirements of
applicable law, in which case this benefit will not apply; 
 (c) the Executive will receive, in a lump sum on the Payment Commencement Date,
the Target Bonus for the fiscal year in which her Date of Termination occurs; 
 (d) each outstanding option to purchase shares of Common
Stock of the Company held by the Executive shall become immediately exercisable in full; and 
 (e) each restricted stock or stock unit award
held by the Executive shall be deemed to be fully vested and free from repurchase and forfeiture provisions, and, to the extent applicable, will no longer be subject to a right of repurchase by or forfeiture to the Company; provided that the vesting
will not accelerate the distribution of shares underlying equity awards if such acceleration of distribution would trigger taxation under Section 409A of the Code. 

6.2 Termination by the Company Without Cause or by the Executive for Good Reason Prior to, or More than 12 Months Following, a Change in
Control. If, prior to a Change in Control Date or more than 12 months following a Change in Control Date, either the Executive’s employment is terminated by the Company without Cause (other than for Disability or death) or the Executive
resigns for Good Reason (a “Non-Change in Control Termination”), then, following the Date of Termination and subject to the conditions of Section 7 and in accordance with the payment terms set
forth in Section 7: 

 (a) the Company shall, for a period of 12 months beginning on the Payment Commencement Date,
continue to pay to the Executive, in accordance with the Company’s customary payroll practices, her then current Base Salary as severance; 

(b) if the Executive is eligible for and timely elects to continue receiving group medical and/or dental insurance under the continuation
coverage rules known as COBRA, the Company will continue to pay the share of the premium for such coverage that it pays for active and similarly-situated employees who receive the same type of coverage (single, family, or other) until the earlier of
(x) the end of the 12th month after the Date of Termination, and (y) the date the covered individual’s COBRA continuation coverage expires, unless, as a result of a change in legal
requirements, the Company’s provision of payments for COBRA will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply; 

(c) the Executive will receive a pro-rated Target Bonus for the fiscal year in which her Date of
Termination occurs, calculated by multiplying the Target Bonus for such year by a fraction, the numerator of which is the number of days the Executive was employed by the Company in such year and the denominator of which is 365, paid in a lump sum
on the Payment Commencement Date; 
 (d) the vesting schedule of each outstanding option to purchase shares of Common Stock of the Company
held by the Executive shall be accelerated in part so that the option shall become exercisable for an additional number of shares equal to 25% of the original number of shares of Common Stock subject to the option; and 

(e) unvested shares, or units, if any, with respect to each restricted stock or stock unit award held by the Executive shall become vested such
that the number of unvested shares or units shall be reduced by 25% of the original number of shares or units subject to such restricted stock or stock unit award; provided that the vesting will not accelerate the distribution of shares underlying
equity awards if such acceleration of distribution would trigger taxation under Section 409A of the Code. 
 For the avoidance of doubt, the equity
acceleration upon a termination of the Executive by the Company without Cause or by the Executive for Good Reason prior to, or more than twelve months following, a Change in Control provided for in Sections 6.2(d) and (e) shall be in lieu of,
and not in addition to, any equity acceleration provided for in any applicable equity award agreement in connection with such a termination (a “Non-CIC Duplicative Acceleration Provision”). The
Executive agrees that any Non-CIC Duplicative Acceleration Provision is hereby deleted and of no further force or effect. 

6.3 Termination by the Company for Cause, by the Executive Without Good Reason, or Due to Death or Disability. If the Company terminates
the Executive’s employment for Cause or the Executive resigns without Good Reason, or if the Executive’s employment terminates due to her death or Disability, then the Company’s obligations under this Agreement shall immediately cease
and the Executive shall be entitled to only the Base Salary that has accrued and to which the Executive is entitled as of the Date of Termination. The Executive shall not be entitled to any other compensation or consideration, including any
Performance Bonus not yet paid, that the Executive may have received had the Employment Period not ended. For the avoidance of doubt, termination of this Agreement by notice of non-renewal by the Executive
will be treated as a termination by the Executive without Good Reason. 

 6.4 Termination Prior to or More Than 12 Months Following a Change in Control Due to
Expiration of the Employment Period by Notice of Non-Renewal. If (a) this Agreement and the employment of the Executive terminate due to expiration of the Employment Period by notice of non-renewal by the Company, and (b) the Date of Termination occurs prior to a Change in Control Date or more than 12 months following a Change in Control Date, and provided that the Executive would otherwise
have been willing and able to continue her employment under the terms of this Agreement but for the Company’s decision not to renew, then such termination will be treated as a Non-Change in Control
Termination. 
 6.5 Termination Within 12 Months Following a Change in Control Due to Expiration of the Employment Period by Notice of Non-Renewal. If (a) this Agreement and the employment of the Executive terminate due to expiration of the Employment Period by notice of non-renewal by the Company,
and (b) the Date of Termination occurs within 12 months following a Change in Control Date, and provided that the Executive would otherwise have been willing and able to continue her employment under the terms of this Agreement but for the
Company’s decision not to renew, then such termination will be treated as a Change in Control Termination. 
 7. Release. The
obligation of the Company to make the payments and provide the benefits to the Executive under Section 6.1, 6.2, 6.4, or 6.5 is conditioned upon the Executive signing and delivering to the Company a severance and release of claims agreement in
a form to be provided by the Company (which will include, at a minimum, a release of all releasable claims and non-disparagement and cooperation obligations) (the “Executive Release”), which
Executive Release must become irrevocable within sixty (60) days following the Date of Termination (or such shorter period as the Company may provide, which shall not be less than 30 days following the Date of Termination). The Company shall
commence or make, as applicable, the payments under Section 6.1, 6.2, 6.4, or 6.5 on the first payroll period following the date the Executive Release becomes irrevocable (such date, the “Payment Commencement Date”); provided,
however, that if the 60th day following the Date of Termination falls in the calendar year following the year of the Executive’s termination of employment, the Payment Commencement Date shall be the first payroll period of such later calendar
year; and provided further that the payment of any amounts pursuant to Section 6.1, 6.2, 6.4, or 6.5 shall be subject to the terms and conditions set forth in Exhibit A. 

8. Termination Obligations. 

8.1 Return of Company’s Property. The Executive hereby acknowledges and agrees that all personal property, including, without
limitation, all books, manuals, records, reports, notes, contracts, lists, blueprints and other documents or materials, or copies thereof, and equipment furnished to or prepared by the Executive in the course of or incident to the Executive’s
employment, belong to the Company and shall be promptly returned to the Company upon termination of the Executive’s employment or earlier request by the Company. Following termination, the Executive will not retain any written or other tangible
material containing any proprietary information or confidential information of the Company. 

 8.2 Cooperation. Following any separation from employment or notice thereof, the Executive
shall fully cooperate with the Company in all matters relating to the winding up of pending work on behalf of the Company and the orderly transfer of work to other executives of the Company. The Executive shall also cooperate in the defense of any
action brought by any third party against the Company that relates in any way to the Executive’s acts or omissions while employed by the Company. 

9. Section 280G. 
 9.1
Notwithstanding any other provision of this Agreement, except as set forth in Section 9.2, in the event that the Company undergoes a “Change in Ownership or Control” (as defined below), the Company shall not be obligated to provide to
the Executive a portion of any “Contingent Compensation Payments” (as defined below) that the Executive would otherwise be entitled to receive to the extent necessary to eliminate any “excess parachute payments” (as defined in
Code Section 280G(b)(l)) for the Executive. For purposes of this Section 9, the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Payments” and the aggregate amount (determined in accordance
with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the
“Eliminated Amount.” 
 9.2 Notwithstanding the provisions of 9.1, no such reduction in Contingent Compensation Payments shall be
made if (i) the Eliminated Amount (computed without regard to this sentence) exceeds (ii) 110% of the aggregate present value (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by the Executive if the Eliminated Payments (determined without
regard to this sentence) were paid to him or her (including, state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in
excess of the Executive’s “base amount” (as defined in Section 280G(b)(3) of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation Payments pursuant to this Section 9.2 shall be
referred to as a “Section 9.2 Override.” For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the
amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law. 
 9.3 For purposes of this
Section 9 the following terms shall have the following respective meanings: 
 (i) “Change in Ownership or Control” shall
mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code. 

(ii) “Contingent Compensation Payment” shall mean any payment (or benefit) in the nature of compensation that is made or made
available (under this Agreement or otherwise) to a “disqualified individual” (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership
or Control of the Company. 

 9.4 Any payments or other benefits otherwise due to the Executive following a Change in Ownership
or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the “Potential Payments”) shall not be made until the dates provided for in this Section 9.4. Within 30 days after
each date on which the Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify the Executive (with reasonable
detail regarding the basis for its determinations) (i) which Potential Payments constitute Contingent Compensation Payments, (ii) the Eliminated Amount and (iii) whether the Section 9.2 Override is applicable. Within 30 days
after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the “Executive Response”) stating either (A) that he or she agrees with the Company’s determination pursuant to the preceding
sentence, or (B) that he or she disagrees with such determination, in which case he or she shall set forth (i) which Potential Payments should be characterized as Contingent Compensation Payments, (ii) the Eliminated Amount, and
(iii) whether the Section 9.2 Override is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company’s initial determination shall be final. If and to the extent that
any Contingent Compensation Payments are required to be treated as Eliminated Payments pursuant to this Section 9, then the payments shall be reduced or eliminated, as determined by the Company, in the following order: (i) any cash
payments, (ii) any taxable benefits, (iii) any nontaxable benefits, and (iv) any vesting of equity awards in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that
triggers the applicability of the excise tax, to the extent necessary to maximize the Eliminated Payments. If the Executive states in the Executive Response that he or she agrees with the Company’s determination, the Company shall make the
Potential Payments to the Executive within three business days following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made
on the date on which they are due). If the Executive states in the Executive Response that he disagrees with the Company’s determination, then, for a period of 60 days following delivery of the Executive Response, the Executive and the Company
shall use good faith efforts to resolve such dispute. If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in the State of Connecticut, in
accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on the arbitrator’s award in any court having jurisdiction. The Company shall, within three business days following delivery to the
Company of the Executive Response, make to the Executive those Potential Payments as to which there is no dispute between the Company and the Executive regarding whether they should be made (except for any such Potential Payments which are not due
to be made until after such date, which Potential Payments shall be made on the date on which they are due). The balance of the Potential Payments shall be made within three business days following the resolution of such dispute. Subject to the
limitations contained in Sections 9.1 and 9.2 hereof, the amount of any payments to be made to the Executive following the resolution of such dispute shall be increased by amount of the accrued interest thereon computed at the prime rate announced
from time to time by The Wall Street Journal, compounded monthly from the date that such payments originally were due. 
 9.5 The provisions
of this Section 9 are intended to apply to any and all payments or benefits available to the Executive under this Agreement or any other agreement or plan of the Company under which the Executive receives Contingent Compensation Payments. 

 10. Non-Competition,
Non-Solicitation, Inventions, and Non-Disclosure Obligations. The Executive hereby reaffirms all of her obligations under the Noncompetition Agreement previously
executed by her dated February 1, 2016 (the “Non-Compete Agreement”), which remains in full force and effect. The Executive further reaffirms all of her obligations under the Nondisclosure and
Assignment of Inventions Agreement previously executed by her dated February 2, 2016 (the “NDA”), which also remains in full force and effect; provided, however, that the Executive hereby agrees that the NDA shall be deemed amended to
include the following as Section 14 thereof: 
 “14. Scope of Disclosure Restrictions. I understand and acknowledge that
nothing in this Agreement or any other Company policy or agreement prohibits me from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies or
participating in government agency investigations or proceedings, and that I am not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information I obtained through a
communication that was subject to the attorney-client privilege. Further, notwithstanding my confidentiality and nondisclosure obligations, I understand that, and the Company is hereby advising me as follows, pursuant to the Defend Trade Secrets
Act: “An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official,
either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such
filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court
proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.” 

11. Absence of Restrictions. The Executive represents and warrants that she is not bound by any employment contracts, restrictive
covenants or other restrictions that prevent her from continuing her employment with, or carrying out her responsibilities for, the Company, or which are in any way inconsistent with any of the terms of this Agreement. 

12. Definitions. For purposes of this Agreement, the following terms shall have the following meanings: 

12.1 “Cause” shall mean (a) a good faith finding by the Company that (i) the Executive has failed to substantially perform
her reasonably assigned duties for the Company, or (ii) the Executive has engaged in dishonesty, gross negligence or misconduct, which dishonesty, gross negligence or misconduct has had a material adverse effect on the Company, (b) the
conviction of the Executive of, or the entry of a plea of guilty or nolo contendere by the Executive to, any felony, (c) breach by the Executive of any material provision of this Agreement or other agreement with the Company (which breach is
not cured within 30 days following written notice by the Company thereof), or (d) breach by the Executive of the Non-Compete Agreement or NDA. 

 12.2 “Change in Control” shall mean the sale of all or substantially all of the capital
stock (other than the sale of capital stock to one or more venture capitalists or other institutional investors pursuant to an equity financing (including a debt financing that is convertible into equity) of the Company approved by a majority of the
Board), assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Common Stock
immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving or acquiring corporation in such
transaction), provided that, where applied to compensation subject to Section 409A, any acceleration of or change in payment shall only apply (if required by Section 409A) if the corporate transaction is also a change in control event
described in Treasury Regulation 1.409A-3(i)(5). 
 12.3 “Change in Control Date” means the
first date during the Employment Period on which a Change in Control occurs. Anything in this Agreement to the contrary notwithstanding, if (a) a Change in Control occurs, (b) the Executive’s employment with the Company is terminated
(i) without Cause (other than due to the Executive’s death or Disability), or (ii) due to expiration of the Employment Period by notice of non-renewal by the Company, within 60 days prior to the
date on which the Change in Control occurs, and (c) it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably calculated to effect a Change in
Control or (ii) otherwise arose in connection with or in anticipation of a Change in Control, then the “Change in Control Date” shall mean the date immediately prior to the date of such termination of employment. Where applicable, the
Company shall take such steps as are reasonably practicable as of the termination date to preserve the availability of equity compensation that may expire (other than by reaching the full term of an option) during the 60 day period (by vesting and
freezing the equity) pending the occurrence of the Change in Control. 
 12.4 “Disability” shall mean the inability of the
Executive, due to a physical or mental disability, for a period of 90 days, whether or not consecutive, during any 360-day period to perform the services contemplated under this Agreement, with or without
reasonable accommodation, as that term is defined under state or federal law. A determination of disability shall be made by a physician satisfactory to both the Executive and the Company, provided that if the Executive and the Company do not agree
on a physician, the Executive and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding on all parties. 

12.5 “Good Reason” shall mean the occurrence, without the Executive’s prior written consent, of any of the following events:
(i) a material diminution of the Executive’s base compensation; (ii) a requirement that the Executive’s principal place of providing services to the Company change by more than 50 miles, other than in a direction that reduces the
Executive’s daily commuting distance; (iii) any material breach by the Company or any successor thereto of a material provision of this Agreement; or (iv) a material diminution in the Executive’s authority, duties, or
responsibilities, provided, however, and for the avoidance of doubt, that Good Reason 

 
shall not exist if the Executive no longer holds the same title or functional role within an entity resulting from a Change in Control, so long as the Executive’s responsibilities are not
substantially diminished. Notwithstanding the occurrence of any of the foregoing events or circumstances, a resignation shall not be deemed to constitute resignation for Good Reason unless (x) the Executive gives the Company a written notice of
the purported Good Reason (no more than 90 days after the initial existence of such event or circumstance), (y) such event or circumstance has not been fully corrected (and the Executive has not been reasonably compensated for any losses or damages
resulting therefrom) within 30 days following the Company’s receipt of such notice, and (z) if the Company does not correct, the Executive ends her employment not more than 30 days following the period to correct in (y). 

13. Miscellaneous. 
 13.1
Entire Agreement; Modification. This Agreement constitutes the entire understanding and agreement between the parties hereto with regard to the subject matter hereof and, as of the Effective Date, supersedes all prior understandings and
agreements, whether written or oral, including, without limitation, the Initial Agreement. For the avoidance of doubt, nothing herein supersedes the Non-Compete Agreement or NDA. The Executive is not relying
on any representations other than those set forth in this Agreement. 
 13.2 Notices. Any notice delivered under this Agreement shall
be deemed duly delivered 3 business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier
service, to the Company at its principal headquarters and to the Executive at the address most recently shown on the personnel records of the Company. Either party may change the address to which notices are to be delivered by giving notice of such
change to the other party in the manner set forth in this Section 13.2. 
 13.3 Pronouns. Whenever the context may require, any
pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

13.4 Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive
and approved by the Board. 
 13.5 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
State of Connecticut (without reference to the conflicts of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court of the State of
Connecticut (or, if appropriate, a federal court located within Connecticut), and the Company and the Executive each consents to the jurisdiction of such a court. The Company and the Executive each hereby irrevocably waives any right to a trial by
jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement. 
 13.6 Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the
Company’s assets or business, provided, however, that the obligations of the Executive are personal and shall not be assigned by her. 

 13.7 Waivers. No delay or omission by the Company in exercising any right under this
Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other
occasion. 
 13.8 Captions. The captions of the sections of this Agreement are for convenience of reference only and in no way define,
limit or affect the scope or substance of any section of this Agreement. 
 13.9 Severability. In case any provision of this Agreement
shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

13.10 Executive’s Acknowledgments. The Executive acknowledges that she: (i) has read this Agreement; (ii) has been
represented in the preparation, negotiation, and execution of this Agreement by legal counsel of the Executive’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement;
(iv) is fully aware of the legal and binding effect of this Agreement; and (v) understands that the law firm of Wilmer Cutler Pickering Hale and Dorr LLP is acting as counsel to the Company in connection with the transactions contemplated
by the Agreement, and is not acting as counsel for the Executive. 
 [Remainder of page is intentionally left blank] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the dates set forth
below. 
 ACHILLION PHARMACEUTICALS, INC. 
  

							
	By:	 	 /s/ Milind S. Deshpande
	  		  	Date: 8/4/17                            
		 	Name: Milind S. Deshpande, Ph.D.	  		  	
		 	Title: Chief Executive Officer	  		  	
			
	EXECUTIVE:	  		  	
			
	 /s/ Martha Manning
	  		  	Date: July 26, 2017                    
	Martha Manning	  		  	

 Exhibit A 

Section 409A 
 The intent of the
parties is that payments and benefits under this Agreement comply with, or be exempt from, Internal Revenue Code Section 409A and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”) and this
Agreement shall be interpreted consistently therewith. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code
Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year,
provided that this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(a) of the Code solely because such expenses are subject to a limit related to the period the arrangement
is in effect, and (iii) such payments shall be made on or before the last day of your taxable year following the taxable year in which the expense occurred, provided that any tax gross-ups may be
reimbursed by the end of the calendar year following the calendar year in which such taxes are remitted to the taxing authorities. For purposes of Code Section 409A, each payment hereunder shall be treated as a separate payment and
Executive’s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. In no event may Executive, directly or indirectly, designate the calendar year
of any payment to be made under this Agreement that is considered nonqualified deferred compensation. Termination of employment as used herein shall mean separation from service within the meaning of Code Section 409A. Notwithstanding anything
in this Agreement to the contrary, to the extent required by Section 409A of the Code, if Executive is considered a “specified employee” for purposes of Section 409A of the Code and if payment of any amounts under this Agreement
is required to be delayed for a period of six months after separation from service pursuant to Section 409A of the Code, payments of such amounts shall be delayed as required by Section 409A of the Code, and the accumulated amounts shall
be paid in a lump sum payment within ten days after the end of the six-month period. If Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on account of
Section 409A of the Code shall be paid to the personal representative of the Executive’s estate within 60 days after the date of Executive’s death. The Company is not making any representation or warranty to Executive with respect to
the treatment of this Agreement under Code Section 409A and shall have no liability to Executive or any other person with respect to payments or benefits under this Agreement should any payments or benefits under this Agreement be determined to
constitute nonqualified deferred compensation subject to Code Section 409A but not satisfying the conditions of such section.EX-10.6

 Exhibit 10.6 

FIRST AMENDMENT TO MASTER SECURITY AGREEMENT 

This First Amendment to Master Security Agreement (this “Amendment”) is made as of the 26th day of May, 2016 between Webster Bank, National Association (“Secured Party”) and Achillion Pharmaceuticals, Inc. (“Debtor”). 

WHEREAS, Secured Party and Debtor entered into that certain Master Security Agreement dated as of October 3, 2014 (the
“Agreement”); and 
 WHEREAS, Secured Party and Debtor desire to amend the Agreement in certain respects and to
ratify and confirm the portions of the Agreement that are not being amended by this Amendment. 
 NOW THEREFORE, in consideration of
the foregoing and the mutual covenants set forth below and intending to be legally bound, the parties hereby agree as follows: 
 (1) Amendments to
Agreement. 
 (a) Section 1(a) of the Agreement is hereby deleted in its entirety and replaced with the following: 

“(a) Equipment Loan Advances. Between October 3, 2014 and the Amendment Effective Date (defined below), Secured Party made
Equipment Loan Advances (defined below) to Debtor in the aggregate amount of THREE HUNDRED NINETY NINE THOUSAND EIGHT HUNDRED SEVENTY SEVEN and 00/100 Dollars ($399,877.00) (the “Existing Advances”). Subject to the terms and
conditions set forth in this Agreement, Secured Party agrees to make additional advances for the purchase of Eligible Equipment (defined below) (each an “Equipment Loan Advance” and collectively, the “Equipment Loan
Advances”) to Debtor from time to time on any business day during the period from October 3, 2014 up to and including May 26, 2017 (the “Drawdown Period”); provided, however, that at no time shall
the aggregate amount of all Equipment Loan Advances (including the Existing Advances) exceed the lesser of (i) one hundred percent (100%) of the documented cost of the Eligible Equipment and (ii) ONE MILLION THREE HUNDRED NINETY NINE
THOUSAND EIGHT HUNDRED SEVENTY SEVEN and 00/100 DOLLARS ($1,399,877.00) (the “Committed Amount”). “Eligible Equipment” for the purposes of this Agreement includes new laboratory equipment excluding shipping
costs, taxes, installation costs and other soft costs. Notwithstanding anything to the contrary contained in this Agreement, (i) any and all Equipment Loan Advances must be made no later than one hundred twenty (120) days after
Debtor’s purchase of Eligible Equipment, (ii) each Equipment Loan Advance must be equal to or greater than $50,000; (iii) the Equipment Loan Advances are limited to two (2) on or after the date on which that certain First
Amendment to Master Security Agreement by and between Debtor and Secured Party is executed (the 

 
“Amendment Effective Date”) and (iv) any Equipment Loan Advance must be made within twelve (12) months from the Amendment Effective Date. Any amounts repaid with
respect to any Equipment Loan Advance may not be reborrowed.” 
 (b) Exhibit A to the Agreement is hereby deleted and
replaced with Exhibit A attached hereto and incorporated herein. 
 (2) Origination Fee. In consideration for Secured Party extending
the Drawdown Period and extending additional credit accommodations to Debtor pursuant to this Amendment, Debtor shall remit to Secured Party on the date hereof an origination fee in the amount of Ten Thousand and 00/100 Dollars ($10,000.00). 

(3) Ratification of Original Agreement. Except as expressly amended hereby, the Agreement shall remain in full force and effect, and is hereby ratified
and confirmed in all respects. 
 (4) Material Adverse Change. Secured Party’s obligation to enter into this Amendment shall terminate if, in
Secured Party’s sole discretion, there has been a material adverse change in the general affairs, management, results, operations, condition (financial or otherwise) of Debtor, whether or not arising from transactions in the ordinary course of
business, or if there has been any material adverse deviation by Debtor from the business plan of Debtor presented to and accepted by Secured Party prior to the execution of this Amendment. 

(5) Miscellaneous. 
 (a) Successors and
Assigns. This Amendment shall inure to the benefit of and shall be binding upon the parties hereto and their respective successors and assigns. 

(b) Severability. If any provision of this Amendment shall be held invalid or unenforceable by any court of competent jurisdiction, such
holding shall not invalidate or render unenforceable any other provision hereof. 
 (c) Modifications in Writing. Amendments or
modifications of any provision of this Amendment (including this paragraph) or any documents delivered in connection herewith shall in no event be effective unless the same shall be in writing and signed by the party against whom enforcement is
sought. 
 (d) Execution and Counterparts. This Amendment may be executed in several counterparts, each of which shall be an original
and all of which shall constitute one and the same document. 
 (e) Captions. The captions and headings in this Amendment are for
convenience only and do not define, limit or describe the intent of any provisions hereof. 

  
 2 

 (f) Definitions. Capitalized terms used herein, but not otherwise defined herein shall
have the meanings given to them in the Agreement. 
 [Signature Page to Follow] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment to Master Security Agreement by
signature of their respective authorized representative set forth below. 
  

									
	Webster Bank, National Association	 		  	Achillion Pharmaceuticals, Inc.
					
	By:	 	 /s/ George Sims
	 		  	By:	  	 /s/ Mary Kay Fenton

	Name:	 	George Sims	 		  	Name:	  	Mary Kay Fenton
	Title:	 	Vice President	 		  	Title:	  	Executive Vice President & Chief Financial Officer

 Exhibit A 

Form of Promissory Note 

PROMISSORY NOTE 
  

(Date) 
 FOR VALUE
RECEIVED, Achillion Pharmaceuticals, Inc. a Delaware corporation located at the address stated below (“Maker”) promises to pay to the order of Webster Bank, National Association or any subsequent holder hereof (each, a
“Payee”) at its office located at 80 Elm Street, New Haven, CT 06510 or at such other place as Payee or the holder hereof may designate, the principal sum of
            Dollars ($            ), pursuant to that certain Master Security Agreement (“MSA”) by and
between Webster Bank, National Association and Achillion Pharmaceuticals, Inc., dated as of October 3, 2014, as amended, restated, amended and restated, supplemented or otherwise modified and in effect from time to time, together with interest
on the unpaid principal balance, from the date hereof through and including the dates of payment, at a fixed interest rate of [the Three Year FHLB Classic Advance Rate (as published on the FHLB website on the date any Equipment Loan Advance is made)
plus 475 basis points] percent (            %) per annum, to be paid in lawful money of the United States, in thirty-six (36) consecutive monthly installments of principal and
interest as follows: 
 Periodic 

Installment
                    Amount 
 each a
“Periodic Installment” and a final installment which shall be in the amount of the total outstanding principal and interest. The first Periodic Installment shall be due and payable on
            and the following Periodic Installments and the final installment shall be due and payable on the first day of each succeeding month (each, a “Payment Date”).
The Periodic Installments have been calculated on the basis of a 360 and actual number of days elapsed. Each payment may, at the option of the Payee, be calculated and applied on an assumption that such payment would be made on its due date.

 All terms and conditions of the MSA are incorporated herein, except that in the event there are any conflicting terms and conditions, the
terms and conditions of this Promissory Note (this “Note”) shall prevail. Capitalized terms used herein but not defined shall have the meaning ascribed thereto in the MSA. 

 The acceptance by Payee of any payment which is less than payment in full of all amounts due and
owing at such time shall not constitute a waiver of Payee’s right to receive payment in full at such time or at any prior or subsequent time. 

The Maker hereby expressly authorizes the Payee to insert the date value as actually given in the blank space on the face hereof and on all
related documents pertaining hereto. 
 This Note may be secured by a security agreement, chattel mortgage, pledge agreement or like
instrument (each of which is hereinafter called a “Security Agreement”). 
 Time is of the essence hereof. If any
installment or any other sum due under this Note or any Security Agreement is not received within ten (10) days after its due date, the Maker agrees to pay, in addition to the amount of each such installment or other sum, a late payment charge
of five percent (5%) of the amount of said installment or other sum, but not exceeding any lawful maximum. If (i) Maker fails to make payment of any amount due hereunder within ten (10) days after the same becomes due and payable; or
(ii) Maker is in default under, or fails to perform under any term or condition contained in any Security Agreement, then the entire principal sum remaining unpaid, together with all accrued interest thereon and any other sum payable under this
Note or any Security Agreement, at the election of Payee, shall immediately become due and payable, with interest thereon at the lesser of eighteen percent (18%) per annum or the highest rate not prohibited by applicable law from the date of
such accelerated maturity until paid (both before and after any judgment). 
 The Maker may prepay its indebtedness hereunder, subject to a
yield maintenance fee computed as follows. The current rate at the time of the prepayment for US Treasury Bills with a maturity date closest to the maturity date of this Note shall be subtracted from the interest rate in effect at the time of the
prepayment. If the result is zero or negative, there shall be no yield maintenance fee. If the result is a positive number, then the resulting percentage shall be multiplied by the amount of the principal balance being repaid, divided by 360 and
multiplied by the number of days remaining to the maturity date of this Note. Said amount shall be reduced to present value by using the above-referenced US Treasury Bill rate and the number of days remaining to the maturity date of the term of this
Note as of the date of repayment. The resulting amount is the yield maintenance fee. 
 It is the intention of the parties hereto to comply
with the applicable usury laws; accordingly, it is agreed that, notwithstanding any provision to the contrary in this Note or any Security Agreement, in no event shall this Note or any Security Agreement require the payment or permit the collection
of interest in excess of the maximum amount permitted by applicable law. If any such excess interest is contracted for, charged or received under this Note or any Security Agreement, or if all of the principal balance shall be prepaid, so that under
any of such circumstances the amount of interest contracted for, charged or received under this Note or any Security 

  
 6 

 
Agreement on the principal balance shall exceed the maximum amount of interest permitted by applicable law, then in such event (a) the provisions of this paragraph shall govern and control,
(b) neither Maker nor any other person or entity now or hereafter liable for the payment hereof shall be obligated to pay the amount of such interest to the extent that it is in excess of the maximum amount of interest permitted by applicable
law, (c) any such excess which may have been collected shall be either applied as a credit against the then unpaid principal balance or refunded to Maker, at the option of the Payee, and (d) the effective rate of interest shall be
automatically reduced to the maximum lawful contract rate allowed under applicable law as now or hereafter construed by the courts having jurisdiction thereof. It is further agreed that without limitation of the foregoing, all calculations of the
rate of interest contracted for, charged or received under this Note or any Security Agreement which are made for the purpose of determining whether such rate exceeds the maximum lawful contract rate, shall be made, to the extent permitted by
applicable law, by amortizing, prorating, allocating and spreading in equal parts during the period of the full stated term of the indebtedness evidenced hereby, all interest at any time contracted for, charged or received from Maker or otherwise by
Payee in connection with such indebtedness; provided, however, that if any applicable state law is amended or the law of the United States of America preempts any applicable state law, so that it becomes lawful for the Payee to receive a greater
interest per annum rate than is presently allowed, the Maker agrees that, on the effective date of such amendment or preemption, as the case may be, the lawful maximum hereunder shall be increased to the maximum interest per annum rate allowed by
the amended state law or the law of the United States of America. 
 The Maker and all sureties, endorsers, guarantors or any others (each
such person, other than the Maker, an “Obligor”) who may at any time become liable for the payment hereof jointly and severally consent hereby to any and all extensions of time, renewals, waivers or modifications of, and all
substitutions or releases of, security or of any party primarily or secondarily liable on this Note or any Security Agreement or any term and provision of either, which may be made, granted or consented to by Payee, and agree that suit may be
brought and maintained against any one or more of them, at the election of Payee without joinder of any other as a party thereto, and that Payee shall not be required first to foreclose, proceed against, or exhaust any security hereof in order to
enforce payment of this Note. The Maker and each Obligor hereby waives presentment, demand for payment, notice of nonpayment, protest, notice of protest, notice of dishonor, and all other notices in connection herewith, as well as filing of suit (if
permitted by law) and diligence in collecting this Note or enforcing any of the security hereof, and agrees to pay (if permitted by law) all expenses incurred in collection, including Payee’s actual attorneys’ fees. Maker and each
Obligor agrees that fees not in excess of twenty percent (20%) of the amount then due shall be deemed reasonable. 
 THE MAKER
HEREBY UNCONDITIONALLY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF, DIRECTLY OR INDIRECTLY, THIS NOTE, ANY OF 

  
 7 

 
THE RELATED DOCUMENTS, ANY DEALINGS BETWEEN MAKER AND PAYEE RELATING TO THE SUBJECT MATTER OF THIS TRANSACTION OR ANY RELATED TRANSACTIONS, AND/OR THE RELATIONSHIP THAT IS BEING ESTABLISHED
BETWEEN MAKER AND PAYEE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT (INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW
AND STATUTORY CLAIMS.) THIS WAIVER IS IRREVOCABLE MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND THE WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS NOTE, ANY RELATED DOCUMENTS,
OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING TO THIS TRANSACTION OR ANY RELATED TRANSACTION. IN THE EVENT OF LITIGATION, THIS NOTE MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 

This Note, the MSA, and any Security Agreement constitute the entire agreement of the Maker and Payee with respect to the subject matter
hereof and supercedes all prior understandings, agreements and representations, express or implied. 
 No variation or modification of this
Note, or any waiver of any of its provisions or conditions, shall be valid unless in writing and signed by an authorized representative of Maker and Payee. Any such waiver, consent, modification or change shall be effective only in the specific
instance and for the specific purpose given. 
 Any provision in this Note or any Security Agreement which is in conflict with any statute,
law or applicable rule shall be deemed omitted, modified or altered to conform thereto. 
 [Signature page follows.] 

  
 8 

 IN WITNESS WHEREOF, the Maker has caused this Note to be duly executed as of the date
first written above. 
  

							
		 		 	Achillion Pharmaceuticals, Inc.
			
	  
	 		 	By:                                   
                                         
                                    
	(Witness)	 		 		  	
	  
	 		 	Name:
	(Print name)	 		 		  	
	  
	 		 	Title:
	(Address)	 		 		  	
		 		 	Federal Tax ID #:                              
                                         
              
			
		 		 	Address: 300 George Street, New Haven, New Haven County, CT 06511

  
 9 

					
	

	  		  	 Webster Bank, N.A.
 157 Church Street

20th Floor
 New Haven, CT 06510 

WebsterBank.com

 July 11, 2017 
 Mary Kay Fenton,
EVP & CFO 
 Achillion Pharmaceuticals, Inc. 
 300 George
Street 
 New Haven, CT 06511 
 Re: Draw Period Extension 

Please be advised that the draw period for the credit facility has been extended to May 28, 2018. Other than the extension of the draw period, there are no
other changes to the terms and conditions for the credit facility. Please acknowledge your concurrence by signing below and returning to my attention. 
  

									
	Webster Bank, NA	 		  	Achillion Pharmaceuticals, Inc.
					
	By:	 	 /s/ George G. Sims
	 		  	By:	 	 /s/ Mary Kay Fenton

	Name:	 	George G. Sims	 		  	Name:	 	Mary Kay Fenton
	Title:	 	Senior Vice President	 		  	Title:	 	EVP & CFO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]